The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review
Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, Zheng Wang · 2024
Read The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review by Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, Zheng Wang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677710.txt.
Description
Hanyi Zhong and co-authors review drug resistance in a fast-growing type of breast cancer, in a paper from 2024. The cancer is driven by a surface protein that targeted drugs aim at, yet many tumors stop responding. The review centers on one cell signal chain that is often changed in cancer. That chain helps cells grow and helps them resist drugs meant to block the main target.
The authors sum up what is known about changes in the chain and how it talks to other signal routes. They then survey drugs aimed at the chain, some in trials and some already on the market. They also flag open questions on safety, rules, and ethics. Responses differ by race and by stage of disease, so the review urges care in matching new drugs to the patients most likely to gain.
Catalog record
| CREATOR | Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, Zheng Wang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |